Pay in 4 interest-free payments of $7.24 Learn more
Ships within 48 hours · Estimated delivery Oct 8 - Oct 13
In the 52-week SURPASS-4 trial TZP was tested versus insulin glargine in diabetic adults and a high CV risk below not sufficient GC at baseline and in therapy with one to three oral glucose-lowering drugs (metformin, sulfonylurea, SGLT2-i)
Week 17 onward: 2.4 mg semaglutide per week, the maximum therapeutic dose used in clinical trials
With supplements Vitamin D - Safe and potentially beneficial
Regular TSH checks ensure that any adjustments to your thyroid medication stay coordinated with your GLP-1 therapy, preventing dangerous interactions or ineffective treatment
Patient education so that unusual symptoms arent ignored
US$ 22.06
US$ 25.81
US$ 23.50
US$ 24.75
US$ 22.02
US$ 29.66
